- Home
- FSM vs DVAX Comparison
FSM vs DVAX Comparison
Compare FSM & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- DVAX
- Stock Information
- Founded
- FSM 1990
- DVAX 1996
- Country
- FSM Canada
- DVAX United States
- Employees
- FSM N/A
- DVAX N/A
- Industry
- FSM Precious Metals
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- FSM Basic Materials
- DVAX Health Care
- Exchange
- FSM Nasdaq
- DVAX Nasdaq
- Market Cap
- FSM 1.4B
- DVAX 1.7B
- IPO Year
- FSM N/A
- DVAX 2004
- Fundamental
- Price
- FSM $4.26
- DVAX $12.45
- Analyst Decision
- FSM Hold
- DVAX Buy
- Analyst Count
- FSM 2
- DVAX 2
- Target Price
- FSM $5.50
- DVAX $23.00
- AVG Volume (30 Days)
- FSM 9.6M
- DVAX 1.8M
- Earning Date
- FSM 03-05-2025
- DVAX 02-20-2025
- Dividend Yield
- FSM N/A
- DVAX N/A
- EPS Growth
- FSM N/A
- DVAX N/A
- EPS
- FSM 0.08
- DVAX 0.15
- Revenue
- FSM $1,025,155,000.00
- DVAX $260,810,000.00
- Revenue This Year
- FSM $26.78
- DVAX $21.64
- Revenue Next Year
- FSM N/A
- DVAX $19.81
- P/E Ratio
- FSM $53.52
- DVAX $82.38
- Revenue Growth
- FSM 38.19
- DVAX N/A
- 52 Week Low
- FSM $2.63
- DVAX $9.74
- 52 Week High
- FSM $6.36
- DVAX $14.30
- Technical
- Relative Strength Index (RSI)
- FSM 42.43
- DVAX 41.74
- Support Level
- FSM $4.19
- DVAX $12.27
- Resistance Level
- FSM $4.70
- DVAX $12.74
- Average True Range (ATR)
- FSM 0.20
- DVAX 0.35
- MACD
- FSM 0.00
- DVAX -0.06
- Stochastic Oscillator
- FSM 19.09
- DVAX 37.39
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.